Immunogenic cell death as a mechanism of synergy between sunitinib and (177)Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors.

Essler M, Veit N, Müller A, Marinova M, Kreppel B

Open source

DOI
10.1038/s41420-026-03344-z
Published
2026 Sep 19
Container
Cell death discovery
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41420-026-03344-z,
  title = {Immunogenic cell death as a mechanism of synergy between sunitinib and (177)Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors.},
  author = {Essler M and Veit N and Müller A and Marinova M and Kreppel B},
  year = {2026},
  journal = {Cell death discovery},
  doi = {10.1038/s41420-026-03344-z},
  url = {https://doi.org/10.1038/s41420-026-03344-z}
}

RIS

TY  - JOUR
TI  - Immunogenic cell death as a mechanism of synergy between sunitinib and (177)Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors.
AU  - Essler M
AU  - Veit N
AU  - Müller A
AU  - Marinova M
AU  - Kreppel B
PY  - 2026
JO  - Cell death discovery
DO  - 10.1038/s41420-026-03344-z
UR  - https://doi.org/10.1038/s41420-026-03344-z
ER  - 

APA

M, E., N, V., A, M., M, M., & B, K. (2026). Immunogenic cell death as a mechanism of synergy between sunitinib and (177)Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors.. Cell death discovery. https://doi.org/10.1038/s41420-026-03344-z

Source records